ZHONGHUA YANGSHENG BAOJIAN ›› 2024, Vol. 42 ›› Issue (8): 40-44.

Previous Articles     Next Articles

Effect of Paclitaxel Injection Combined with Carboplatin on Immune Function in Patients with Ovarian Cancer

YU Xia1, QI Hui-li2, *, ZHANG Chun-hong3   

  1. 1. Pharmacy Department of Shihezi People's Hospital, Xinjiang Shihezi 832000, China;
    2. Department of Gynecology, Shihezi People's Hospital, Xinjiang Shihezi 832000, China;
    3. Gynecology of Bazhou People's Hospital, Xinjiang Korla 841000, China
  • Online:2024-04-16 Published:2024-04-08

PDF (PC)

14

Abstract: Objective To investigate the effect of paclitaxel injection combined with carboplatin on immune function in patients with ovarian cancer. Methods 70 patients with ovarian cancer admitted to Shihezi People's Hospital of Xinjiang from January 2019 to January 2023 were retrospectively analyzed, according to treatment methods, the patients were divided into observation group (n=35) and control group (n=35). The control group was treated with carboplatin after confirmed pathological diagnosis and hospitalization, and the observation group was treated with paclitaxel injection combined with carboplatin after confirmed pathological diagnosis and hospitalization. The clinical efficacy, the expression level of tumor marker angiogenesis factor before and after treatment, and the immune function changes of the two groups were compared. Results The objective remission rate and disease control rate of the observation group were significantly higher than those of the control group (P<0.05); There was no significant difference in the levels of bFGF, VEGF angiogenic factor, CA125, and Cyfra21-1 tumor markers between the two groups of patients before treatment (P>0.05). After treatment, the levels of bFGF, VEGF angiogenic factor, CA125, and Cyfra21-1 tumor markers decreased in both groups of patients, and the observation group was lower than the control group (P<0.05); Before treatment, there was no significant difference in the CD4+, CD3+, and CD4+/CD8+values between the two groups of patients. After treatment, the CD4+, CD3+, and CD4+/CD8+ values of the two groups of patients decreased, and the observation group was higher than the control group (P<0.05). Conclusion The combination of paclitaxel injection and carboplatin has a significant therapeutic effect on ovarian cancer, which can inhibit tumor progression, reduce the expression levels of tumor markers and angiogenic factors, and alleviate immune function damage in patients during chemotherapy. It is worthy of clinical application and promotion.

Key words: paclitaxel, carboplatin, oophoroma, immunity, clinical efficacy, tumor markers

CLC Number: